FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to a pharmaceutical combination containing ALK inhibitor in a free form or its pharmaceutically acceptable salt and SHP2 inhibitor in a free form or its pharmaceutically acceptable salt, and to its use. A pharmaceutical combination is proposed for the treatment of ALK-positive cancer, including (i) ALK inhibitor or its pharmaceutically acceptable salt, where ALK inhibitor is ceritinib, and (ii) SHP2 inhibitor and, optionally, a pharmaceutically acceptable carrier for simultaneous or subsequent injection. The combination is suitable for the treatment of cancer with rearranged ALK. Joint targeting on ALK and SHP2 amplifies an antiproliferative effect of ALK inhibitor, even in case of cancer resistant to ALK inhibitor.
EFFECT: inventions provide the reduction in RAS-GTP loading cell potential and inhibit the restoration of phospho-ERK, which can overcome non-targeted resistance in cancer with rearranged ALK, such as NSCLC.
15 cl, 4 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND COMPOSITIONS FOR SUPPRESSING SHP2 ACTIVITY | 2017 |
|
RU2744988C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| DYETERED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH CONNECTIONS | 2014 |
|
RU2632907C2 |
| PROTEIN TYROSIN PHOSPHATASE INHIBITORS | 2020 |
|
RU2799449C2 |
| DI(ARYLAMINO)ARYL COMPOUNDS | 2008 |
|
RU2463299C2 |
| SELECTIVE INHIBITORS OF Haspin kinase | 2012 |
|
RU2548363C2 |
| BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2018 |
|
RU2776846C2 |
| 8-(1-{4-{(5-CHLORO-4-{(2-(DIMETHYLPHOSPHORYL)PHENYL)AMINO}PYRIMIDIN-2-YL)AMINO)-3-METHOXYPHENYL}PIPERIDIN-4-YL)-1-METHYL-1,8-DIAZASPIRO(4.5)DECAN-2-ONE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AS AN ALK AND EGER MODULATOR FOR TREATMENT OF CANCER | 2017 |
|
RU2654695C1 |
| DERIVATIVE OF PYRIMIDINE AND A FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLE, METHOD FOR PRODUCTION AND MEDICAL APPLICATIONS THEREOF | 2019 |
|
RU2775229C1 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
